Hammond; H. Kirk

Patent Applications and Registrations

Patent applications and USPTO patent grants for Hammond; H. Kirk.The latest application filed is for "method of treating type i diabetes using an aav vector encoding uracortin 2".

Company Profile

4.9.11

Hammond; H. Kirk - La Jolla CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function Grant 11,040,091 - Hammond , et al. June 22, 2	2021-06-22
Method of treating type I diabetes using an AAV vector encoding uracortin 2 Grant 10,918,738 - Hammond , et al. February 16, 2	2021-02-16
Method Of Treating Type I Diabetes Using An Aav Vector Encoding Uracortin 2 App 20190367945 - HAMMOND; H. Kirk ; et al.	2019-12-05
Compositions And Methods For The Treatment Or Prevention Of Heart Failure App 20190264189 - HAMMOND; H. Kirk ; et al.	2019-08-29
Method of treating type I diabetes using an AAV vector encoding uracortin 2 Grant 10,202,618 - Hammond , et al. Feb	2019-02-12
Systemic Delivery And Regulated Expression Of Paracrine Genes For Cardiovascular Diseases And Other Conditions App 20180010148 - HAMMOND; H. Kirk ; et al.	2018-01-11
Systemic Delivery Of Virus Vectors Encoding Urocortin-2 And Related Genes To Treat Diabetes-related Cardiac Dysfunctions And Congestive Heart Failure App 20160166651 - HAMMOND; H. Kirk ; et al.	2016-06-16
Cycle Adenosine Monophosphate-incompetent Adenylyl Cyclase And Compositions And Methods For Treating Heart Failure And Increasing Cardiac Function App 20160101164 - HAMMOND; H. Kirk ; et al.	2016-04-14
Systemic Delivery And Regulated Expression Of Paracrine Genes For Cardiovascular Diseases And Other Conditions App 20150118287 - Hammond; H. Kirk ; et al.	2015-04-30
Techniques And Compositions For Treating Cardiovascular Disease By In Vivo Gene Delivery App 20090082293 - GIORDANO; Frank J. ; et al.	2009-03-26
Polynucleotide encoding human adenylylcyclase VI and uses thereof for enhancing cardiac function Grant 7,235,236 - Hammond , et al. June 26, 2	2007-06-26
Techniques and compositions for treating cardiovascular disease by in vivo gene delivery App 20060286072 - Giordano; Frank J. ; et al.	2006-12-21
Gene therapy for congestive heart failure App 20050250721 - Hammond, H. Kirk ; et al.	2005-11-10
Adenovirus encoding human adenylylcyclase (AC) VI Grant 6,752,987 - Hammond , et al. June 22, 2	2004-06-22
Techniques and compositions for treating cardiovascular disease by in vivo gene delivery App 20030148968 - Hammond, H. Kirk ; et al.	2003-08-07
Gene therapy for congestive heart failure App 20020103147 - Hammond, H. Kirk ; et al.	2002-08-01
Gene therapy for congestive heart failure Grant 6,306,830 - Hammond , et al. October 23, 2	2001-10-23
Gene therapies for enhancing cardiac function Grant 6,174,871 - Hammond , et al. January 16, 2	2001-01-16
Gene therapies for enhancing cardiac function Grant 6,100,242 - Hammond , et al. August 8, 2	2000-08-08
Gene transfer-mediated angiogenesis therapy Grant 5,792,453 - Hammond , et al. August 11, 1	1998-08-11

Company Registrations

NCAGE Code	4DGD3	HAMMOND, H KIRK
CAGE Code	4DGD3	HAMMOND, H KIRK

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.